Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience (Q37280734)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 May 2009

Language	Label	Description	Also known as
English	Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience	scientific article published on 18 May 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

blood–brain barrier

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Gene H. Barnett

5

object named as

Gene H Barnett

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

18

object named as

Edward A Neuwelt

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

Lilyana Angelov

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Nancy D Doolittle

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Dale F Kraemer

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Tali Siegal

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

David M Peereboom

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Glen Stevens

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

John McGregor

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Kristoph Jahnke

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Cynthia A Lacy

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Nancy A Hedrick

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Edna Shalom

12

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sandra Ference

13

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Susan Bell

14

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Lisa Sorenson

15

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Rose Marie Tyson

16

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Marianne Haluska

17

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

18 May 2009

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

27

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

21

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

3503-3509

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Strategies to advance translational research into brain barriers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

6 September 2017

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

6 September 2017

Chemotherapy delivery issues in central nervous system malignancy: a reality check.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

6 September 2017

Seizure-promoting effect of blood-brain barrier disruption

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

6 September 2017

Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

6 September 2017

Implications of the blood-brain barrier in primary central nervous system lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

6 September 2017

Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

6 September 2017

Delayed neurotoxicity in primary central nervous system lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

6 September 2017

Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

6 September 2017

Cognitive status and quality of life after treatment for primary CNS lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

6 September 2017

Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

6 September 2017

Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

6 September 2017

MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

6 September 2017

Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

14 September 2017

Current status and future of relapsed primary central nervous system lymphoma (PCNSL).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

14 September 2017

Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

28 September 2017

Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

26 June 2018

Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

26 June 2018

Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

26 June 2018

Combined modality therapy for primary CNS lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

26 June 2018

Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

Cognitive functions in survivors of primary central nervous system lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

Treatment for primary CNS lymphoma: the next step

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717756

3 September 2018

Neuropsychological Assessment Outcomes of Nonacquired Immunodeficiency Syndrome Patients with Primary Central Nervous System Lymphoma before and after Blood-Brain Barrier Disruption Chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19451444

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19451444

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term survival in primary CNS lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19451444

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary CNS lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19451444

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report

1 reference

https://pubmed.ncbi.nlm.nih.gov/19451444

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19451444

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19451444

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement

1 reference

https://pubmed.ncbi.nlm.nih.gov/19451444

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19451444

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.19.3789

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37280734&oldid=2225425953"